FIELD: medicine.
SUBSTANCE: present invention relates to imidazooxazine compound of formula (I) or a salt thereof, wherein A, B, C and D represent N or C-R1a, N atom, or C-R1b, N atom, or C-R1c, and N or C-R1d respectively; R1a, R1b, R1c and R1d are identical or different from each other and each represents hydrogen, halogen, cyano, C1-6alkyl which may contain a hydroxyl group(s) as a substitute(s), C1-6alkoxy carbonyl, comprising hydroxyl, amino or mono- or di- (C1-6alkoxy) amino as substitutes, optionally substituted mono- or di (C1-6alkyl) aminocarbonyl or pyrazole; R2 represents phenyl, pyridyl or thienyl; and R3 and R4 are identical or different from each other and each represents hydrogen, hydroxy, C16alkyl or C3-7cycloalkyl.
EFFECT: obtaining a pharmaceutical composition based on said compounds, having antitumor activity, AKT inhibitor, method of treating and preventing cancer and use of said compounds for preparing an anticancer agent.
12 cl, 6 tbl, 64 ex
Title | Year | Author | Number |
---|---|---|---|
ANTITUMOR EFFECT AMPLIFYER CONTAINING IMIDAZOOXAAZINE COMPOUND | 2013 |
|
RU2618423C2 |
BICYCLIC NITROIMIDAZOLES COVALENTLY CONNECTED TO REPLACED PHENYLOXAZOLYDINONES | 2009 |
|
RU2504547C2 |
USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
DISPIROPYRROLIDINE DERIVATIVES | 2012 |
|
RU2612534C2 |
IMIDAZOPYRIDIN-2-ONE DERIVATIVES, HAVING mTOR INHIBITING ACTIVITY | 2009 |
|
RU2478636C2 |
6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEINKINASE INHIBITORS | 2005 |
|
RU2379308C2 |
TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
BICYCLIC COMPOUND | 2013 |
|
RU2640416C2 |
BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
NEW NICOTINAMIDE DERIVATIVE OR SALT THEREOF | 2011 |
|
RU2560163C2 |
Authors
Dates
2016-03-27—Published
2012-04-05—Filed